AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02664974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate.
Study NCT02664974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported.
Study NCT03556202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study NCT03907111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan Gauze
Description: Gauze made by chitosan material
Study NCT03907111 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: traditional gauze
Study NCT03965754 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social norms
Description: This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
Study NCT03965754 — intervention group
Intervention type: BEHAVIORAL
Intervention: Loss framing
Description: This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
Study NCT03965754 — intervention group
Intervention type: BEHAVIORAL
Intervention: Email reminder
Description: This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
Study NCT00883831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized manual acupuncture
Description: Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
Study NCT03556254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GGT
Description: In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
Study NCT03556254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGT
Description: In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
Study NCT04860531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Facet Joints intra-articular injection with Platelet Rich Plasma
Description: Floroscopy guided by C-arm Intraarticular injection in Lumbar facet Joints
Study NCT04860531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Facet Joints intra-articular injection with a mixture of 0.5% lidocaine and 5mg/ml of betamethasone
Description: Lumbar Facet Joints intra-articular injection
Study NCT01479777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Stepping (RT600 from Restorative Therapies, INC.)
Description: You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
Study NCT00475839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tension-free Vaginal Tape
Study NCT00475839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monarc sub-fascial hammock
Study NCT03104465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: interactive. web-based mindfulness training complemented with mobile application
Study NCT02455960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
Study NCT02455960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01435876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post exercise Surgery
Description: ORTHOPTICS/MINUS LENS THERAPY
Study NCT01435876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthoptics
Description: MINUS LENS THERAPY/ ORTHOPTICS
Study NCT01435876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postop orthoptics
Description: ORTHOPTICS/MINUS LENS THERAPY
Study NCT01435876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Post exercises surgery
Description: UNIOCULAR/BINOCULAR RECESSION/RESECTION
Study NCT05413954 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group ate snacks composed of dried vegetables, one classical egg yolk and 2.3g of sunflower oil during 10 weeks
Study NCT05413954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test
Description: Tes group ate snacks composed of dried vegetables, one test egg yolk naturally enriched in rumenic acid, docosahexaenoic acid and punicic acid, 0.34g of pomegranate seed oil and 2.26g of olive oil during 10 weeks
Study NCT01777503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: prasugrel 5 mg o.d.
Study NCT01777503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg o.d.
Study NCT01126242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tape
Description: Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
Study NCT01126242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tape
Description: Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
Study NCT01126242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Semi rigid brace
Description: Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
Study NCT01126242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi rigid brace
Description: Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
Study NCT01126242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lace-up brace
Description: Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
Study NCT01126242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lace-up brace
Description: Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
Study NCT02254980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitamin-E diffused polyethylene acetabular component
Description: Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
Study NCT02254980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard polyethylene acetabular component
Description: Patients will undergo total hip arthroplasty using a standard cemented acetabular component
Study NCT00379392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Imagery only
Description: Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
Study NCT00379392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mental Imagery and Constraint induced therapy
Description: Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
Study NCT04004481 — intervention group
Intervention type: DRUG
Intervention: Postoperative analgesia using tramadol
Description: Tramadol 100 mg will be given to the patients in the postoperative period.
Study NCT03975933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at Baseline
Description: Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
Study NCT03975933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Free pregnancy test for the future use
Description: We will provide a free pregnancy test in for the future use.
Study NCT03975933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test for the future use with randomzied price
Description: We will provide an opportunity to buy a pregnancy test for the future use with randomized price.
Study NCT01473264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human CC10 (rhCC10)
Description: 5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
Study NCT01473264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human CC10 (rhCC10)
Description: 1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
Study NCT01473264 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
Study NCT03329339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 L PEG with ascorbic acid with prepackaged, low residue diet
Description: Participants who were allocated to the 2 L PEG with ascorbic acid (PEGA) group took 250 ml of PEG with ascorbic acid at 15-min intervals, completing 1 L of the PEG with ascorbic acid protocol at 8:00 PM on the day prior to the procedure. The remaining 1 L of the PEG with ascorbic acid solution was administered in the same manner at 6:00 AM on the day of the procedure. Participants assigned to the 1 L PEG with ascorbic acid with PLD (PLD) group consumed a prepackaged, low residue diet (ZeroCol, Korea Medical Food Inc., Seoul, Korea) which consisted of a breakfast, lunch and dinner, the day prior to colonoscopy. The Participants took 1 L PEG with ascorbic acid solution at 6:00 AM on the day of the colonoscopy in the same way as described above. All of the subjects ingested 500 mL of water for every 1 L of 1 L PEG with ascorbic acid solution consumed. The Participants completed all of the administrations at least 2 hours before the colonoscopy.
Study NCT00408512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiazides
Description: Up to 25 mg per day
Study NCT03485235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D&C
Description: Dilatation and curettage
Study NCT00408512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non thiazidic treatment
Description: Amximum tolerated dosage as indicated from the label
Study NCT00313963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
Study NCT00313963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
Study NCT02497586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopy
Description: Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
Study NCT03479398 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) is an evidence-based psychotherapy that treats a variety of disorders. In this study, clinicians will be enrolled who use types of CBT for anxiety disorders, depression and PTSD in their routine clinical practice. CBT is usually a 12-16 session treatment that focuses on intervening on disorders cognitively and behaviorally through the use of worksheets during session and outside of session.
Study NCT03485235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICSI
Description: Intra Cytoplasmic Sperm Injection
Study NCT01215773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching to HEA 200 mg tablet, oral administration
Study NCT01215773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: High dose oral administration
Study NCT01215773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: Medium dose oral administration
Study NCT03170544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 4.0 nmol/kg
Description: MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study NCT03170544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 8.0 nmol/kg
Description: MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study NCT03170544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 16 nmol/kg
Description: MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study NCT03170544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 32 nmol/kg
Description: MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study NCT03170544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1092, 64 nmol/kg
Description: MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
Study NCT00235989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1b (Betaseron, BAY86-5046)
Description: 250 mcg administered s.c.(subcutaneous) every other day
Study NCT00235989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (Betaseron, BAY86-5046)
Description: 250 mcg administered s.c. every other day (for patients having received 500 mcg before)
Study NCT00235989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (Betaseron, BAY86-5046)
Description: 500 mcg administered s.c. every other day
Study NCT00235989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (Betaseron, BAY86-5046)
Description: 500 mcg administered s.c. every other day (for patients having received 250 mcg before)
Study NCT03870152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery Ablation (EC)
Description: For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC bronchoscopy in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment bronchoscopy confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
Study NCT03734471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reactor Device
Description: The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
Study NCT03734471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tube thoracostomy
Description: Traditional chest tube placement